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journal homepage: http://www.elsevier.com/locate/pjnnsAmyotrophic lateral sclerosis (ALS) is the most frequent adult-
onset motor neuron disease. It involves damage of the upper
motor neuron within the motor cortex and the lower motor
neuron in the nuclei of the cranial nerves and alpha motor
neurons of the spinal cord. The disease mechanism is complex
and involves disturbed mRNA metabolism, glutamate excito-
toxicity, cytoskeletal defects and altered axonal transport,
hyperactivation of microglia, disturbance of protein quality
control and oxidative stress [1]. In approximately 70% of cases
the disease starts in limbs (impaired manual skills or foot
drop), while in 30% of patients it ﬁrst involves bulbar muscles
leading to dysarthria and dysphagia. In rare cases (<1%) the
ﬁrst symptoms are head drop or respiratory distress. Along
with disease progression, ALS leads to respiratory insufﬁcien-
cy, quadriplegia with muscle wasting, loss of useful speech
and swallowing. Death, mainly due to the respiratory
insufﬁciency, follows after 3–5 years from the ﬁrst symptoms'
onset. In 10% of cases the disease lasts for over 10 years or less
than 1 year [2,3].
Although ALS is a rare disease with the overall incidence of
1.75 in 100 000 population/year, and prevalence of approxi-
mately 6 cases per 100 000, there are nearly 450 000 people
living with ALS worldwide [4,5]. In 1995 the Food and Drug
Administration (FDA) approved riluzole for the treatment of
ALS. The drug was registered in Europe in 1996, but in some
countries it became refunded as late as in 2010. Riluzole blocks
the NMDA receptors, decreases glutamate concentration in
the synaptic cleft, increases its reuptake what leads to
decreased inﬂux of calcium ions and exaggerated activation
of the cell metabolism, called excitotoxicity [6]. Unlike
hundreds of other compounds studied throughout the years,
riluzole was the only drug able to modify ALS clinical outcome.
The treatment has not however fulﬁlled the patients' needs.
Riluzole neither improves the clinical state, nor affects the
muscle strength or stops disease progression. It only modestly
prolongs mechanical ventilation-free survival by 2–3 months if
taken for the ﬁrst 18 months of disease duration [7]. For these
reasons, an approval of edaravone, a new drug modifying ALS
progression, caused enthusiasm among ALS patients.
Considering the serious nature of the disease, which
inevitably leads to death in a short time-period, and aprolonged lack of effective treatment, edaravone (Radicava,
Mitsubishi Tanabe Pharma America) was approved by FDA for
the treatment of ALS in May 2017, after only one small positive
clinical trial of short duration [8]. The drug had earlier been
registered in Japan and South Korea (under a brand name of
Radicut) for the treatment of acute stroke (2001), and ALS (2015)
[9]. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a
neuroprotective compound. Its mechanism of action in the
treatment of ALS is not clear but most probably based on
radical scavenging properties [10].
In physiological conditions, edaravone is present in both
dissociated (anionic) hydrophilic form and non-dissociated,
neutral lipophilic form [11]. It is therefore active in the
cytoplasm, where it neutralizes free oxygen species by adding
a spare electron. The lipophilic properties, on their turn,
enable diffusion through the cell membranes [9,11]. In
preclinical studies edaravone was effective against lipophilic
radical oxygen species (similarly to vitamin E), as well as the
hydrophilic ones (like in the case of ascorbic acid). It has shown
neuroprotective properties toward neurons, as well as the
ability to suppress inﬂammatory response of the activated
microglia [11].
In serum 90% of edaravone binds to proteins and its half-
life ranges from 4.5 to 6 h [10]. The drug is metabolized in liver
and kidneys. In doses used in humans, edaravone and its
metabolites do not inﬂuence the metabolism of CYP450 [12].
The pharmacokinetics of edaravone does not depend on age,
gender and body mass. A study performed in a group of 86
healthy volunteers showed no clinically signiﬁcant differences
in the pharmacokinetics and pharmacodynamics between the
population of Caucasian and Japanese origin [13]. Pharmaco-
kinetic data on individuals with renal or liver insufﬁciency are
however lacking [12].
The safety and efﬁcacy of edaravone in ALS was studied in
206 patients in a randomized, double-blind, placebo-con-
trolled trial (MCI186-16) [14]. After 3 months of clinical
observation, patients received either edaravone or placebo
for 6 months. The studied compounds were infused intrave-
nously once a day: for 14 days in the ﬁrst cycle, followed by a
14-day-wash out period, and for 10 out of 14 days of the month
followed by a 14-day long drug-holiday in cycles 2–6. The
Table 1 – Summary of clinical trials with edaravone in patients with amyotrophic lateral sclerosis (ALS).
Study Treatment
duration
Number of
participants
Inclusion
criteria
Primary end-points Secondary
end-points
Result Adverse effects
MCI186-16 randomized,
double blind, placebo-
controlled study [14]
6 months n = 104 edaravone,
n = 102 placebo
Deﬁnite/
probable/
probably
laboratory
supported ALS,
disease
duration ≤ 36
months,
FVC ≥ 70%, 4
points at all
ALSFRS-R
respiratory
items
ALSFRS-R at 6 months from
baseline
%FVC, grip/
pinch strength,
Modiﬁed Norris
Scale, ALSAQ-
40, time till
death or till
reaching
milestones of
disease
progression
(loss of
unassisted
walking/upper
limb functions,
artiﬁcial
ventilation of
gastrostomy)
Negative
(positive result
in post-hoc
analysis in a
subgroup of
patients [17])
Equal frequency
in edaravone
and placebo
group
MCI186-17 double-blind
randomized, prolongation
of MCI186-16 study [15]
6 months (12
months
including the
double-blind
M186-16 study
period)
followed by a 3-
month open-
label edaravone
phase
n = 48 edaravone
(from MCI186-16)–
edaravone group,
n = 45 edaravone-
placebo group,
n = 88 placebo-
edaravone group
As above As above as above Negative Higher
frequency in
edaravone
group
Open label extension study
of MCI-186 [16]
6 months (12
months
including the
double-blind
M186-16 study
period)
n = 65 edaravone
(from MCI-186
group)–edaravone,
n = 58 placebo-
edaravone, n = 0
placebo-placebo
Deﬁnite/
probable ALS,
disease
duration ≤ 24
months,
FVC ≥ 80%, ≥2
points on all 12
ALSFRS-R items
ALSFRS-R, %FVC, Modiﬁed
Norris Scale score, ALSAQ-
40, time to death or till
reaching milestones of
disease progression (loss of
unassisted walking/upper
limb functions, artiﬁcial
ventilation of gastrostomy)
Negative Equal
frequency in
edaravone and
placebo group
MCI186-18 randomized,
double-blind,
placebo-conrolled study [18]
6 months n = 13 edaravone,
n = 12 placebo
Deﬁnite/
probable/
probably
laboratory
supported ALS,
FVC ≥ 60%,
disease
duration ≤ 36
months
ALSFRS-R, %FVC, Modiﬁed
Norris Scale score, ALSAQ-
40, grip/pinch strength and
time to death or till
reaching milestones of
disease progression (loss of
unassisted walking/upper
limb functions, artiﬁcial
ventilation of gastrostomy)
Negative Equal
frequency in
edaravone and
placebo group
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n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 1 2 4 – 1 2 8126primary end-point was a change of ALSFRS-R at 6 months from
baseline. The secondary end-points are summarized in Table 1.
The overall result of the study was negative. A prolongation
study (MCI186-17), in which after 6 months of treatment with
edaravone the patients were again randomized to receive
either edaravone or placebo for 6 months followed by a 3-
month open-label edaravone phase, did not show drug-
induced beneﬁt [15]. The study showed more serious adverse
effects associated with ALS progression in the edaravone
group possibly due to asymmetric randomization (a higher
percentage of older patients in the edaravone group).
However a post-hoc analysis of the data from the MCI186-
16 study revealed that edaravone might have a positive effect
on subgroup of patients in an early stage of ALS and deﬁnite or
probable diagnosis [17]. The patients who could potentially
proﬁt from the treatment had disease duration of less than 24
months, FVC ≥80% and obtained ≥2 points in every item of
ALSFRS-R (subtle speech and swallowing problems, able to
self-feed, and self-dressing, walking without assistance, no
indications for gastrostomy and ventilation support).
Based on this analysis, in 2011 a new smaller phase 3 study
was launched, which enrolled exclusively patients fulﬁlling
the above-mentioned criteria [8]. Indeed, edaravone showed a
beneﬁt after 6 months of treatment. There was a signiﬁcantly
smaller decline of ALSFRS-R score compared with placebo
(5.01  0.64 vs. 7.50  0.66, p = 0.0013), better outcome on
the modiﬁed Norris scale and ALSAQ-40. In their conclusions
the authors pointed out there was no indication that
edaravone might be effective in a wider population of patients
with ALS who did not meet the criteria [8]. There was also a
randomized, double-blind placebo-controlled study in a group
of 25 patients with advanced ALS. It enrolled patients with
clinically deﬁnite, probable or probable-laboratory supported
ALS, FVC > 60% and disease duration <36 months. Although
there were no differences in the frequency of adverse events
between the groups, the study failed to reach statistical power
and did not show clinical beneﬁts after 6 months [18].
For this reason, a very fast approval of edaravone for the
treatment of the entire population of ALS patients raised
serious considerations among the neurologist involved in the
ALS care.
European Network for he Cure of ALS (ENCALS) published
a statement addressing some crucial issues considering the
available information on the potential beneﬁt of edaravone
[19]. The authors emphasized that edaravone registration
was based on a single clinical trial performed in a small
(n = 137) group of patients in one population. A short trial
duration (6 months) did not allow for analysis of survival.
Despite the fact the treatment signiﬁcantly reduced disease
progression and positively inﬂuenced the quality of life in a
subgroup of ALS patients fulﬁlling speciﬁc criteria, the
authors pointed out at a very fast disease progression in
the ALS placebo group (7.5 points in ALSFRS-R/6 months)
compared to earlier studies, which showed ALSFRS-R
decrease at 5.6 points/6 months on average. It might again
suggest an asymmetric randomization, which could have
inﬂuenced the study outcome. The same issue was brought
up in the correspondence to Lancet Neurology [20]. ENCALS
encouraged Mitsubishi Tanabe Pharma (MT Pharma) to
conduct a longer trial in Europe.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 1 2 4 – 1 2 8 127In response to the ENCALS statement, the company
performed a study, which compared demographic and clinical
data of Japanese, US and European ALS patients who
participated in 12 clinical trials published since 2000 [21]. No
signiﬁcant differences were found between the familial/
sporadic cases, bulbar/limb onset, diagnosis delay, or disease
progression. As compared to European and US studies (n = 10),
the patients participating in 2 Japanese (edaravone) clinical
trials had a lower BMI, higher use of riluzole and shorter disease
duration. The progression rate in patients who received
placebo, as assessed by slope changes in the ALSFRS-R score
ranged from 6.2 to 7.3/6 months in the Japanese patients as
compared to – 5.3–9.6/6 months in the European and US
patients. Based on the above comparison the authors conclud-
ed that there was evidence to support the generalizability of
data from the Japanese ALS trial experience to the US and
Europe populations in early to mid-stage of ALS [21].
The MT Pharma performed an indirect analysis of the effect
of edaravone on the function of muscle groups (bulbar, arms,
legs, respiratory) based on the ALSFRS-R outcome. The
analysis concerned the change in the ALSFRS-R items and
domains at the end of the positive phase 3 study compared to
baseline [8,22]. It showed that edaravone slowed functional
decline across all 4 anatomical regions. The favorable effect
was present in patients with either bulbar or limb onset [21].
After completion of the 6-month double-blind study, patients
from edaravone (n = 65) and placebo (n = 58) groups received
edaravone for further 6 months in an open-label trial [23]. The
analysis showed a better clinical outcome of patients who
received edaravone treatment for 12 months as compared to a
6-month-treatment.
A combined analysis of adverse events was performed
based on the results of three phase 3 studies, which included
the total of 368 ALS patients (n = 184 in the edaravone and
placebo group each) [17,24]. The frequency of adverse effects
requiring treatment was equal in both groups (87.5 vs. 87.0%,
respectively) and it was stable throughout the treatment
period. Serious adverse events included disease-attributed
respiratory disorders and dysphagia (17.4% vs. 22.3%). Only
2.2% patients discontinued treatment in the edaravone and
5.4% in the placebo group, while 3.3% patients died during the
study due to respiratory insufﬁciency (2.2% and 1.1%,
respectively). Commonly reported adverse events that were
more frequent in the edaravone group included contusion, gait
disturbance, headache, skin changes, respiratory disorder and
glucosuria [24]. Since hypersensitivity reactions and anaphy-
lactic reactions were reported in spontaneous postmarketing
reports, the drug is contraindicated in patients with a history
of hypersensitivity to edaravone or any of the inactive
ingredients of the product. The sodium bisulﬁte present in
the solution may cause allergic type-reactions, including
anaphylactic symptoms and life-threatening or less severe
asthmatic episodes in susceptible people, more probably in
patients suffering from asthma [12].
Based on the data published to date we can summarize that
edaravone is a drug, which decreases disease progression in
early-stage of ALS in self-dependent patients with no
respiratory involvement and indications for gastrostomy. It
can be safely used for 12 months provided precautions
considering allergic-type reactions in predisposed patients.Treatment decisions should however be taken after a careful
consideration of organization and administrative issues.
Intensive as it is, the edaravone treatment requires careful
time planning. The drug is given intravenously once daily for
14 days followed by a two-week break. In consecutive cycles it
may be administered for 10 out of the ﬁrst 14 days of the month
again followed by a fortnight break. Each infusion lasts for
approximately 60 min and for safety reasons at least the ﬁrst
two cycles should be administered at hospital settings [19].
Therefore the patients should be prepared to spend half of
every month on treatment. Not only do they have to consider
the primary need for hospitalization, but also the localization
and commute to the infusion center or logistics of home
infusions. The costs of the drug range from 220 to 1000 USD/
infusion, excluding the hospitalization expenditure, com-
mute, work-absence days, involvement of the care-giver, etc
[25]. Altogether, despite the fact edaravone was proved to
increase the quality of life, its costs and way of administration
may negatively inﬂuence the compliance of some patients. On
the other hand, there are patients who may proﬁt from certain
regularity in treatment, which gives them a feeling of an active
launch against the disease [25].
With all the pros and cons, edaravone has brought a new
treatment strategy into the ALS ﬁeld [26]. For the ﬁrst time in
the history of drug research in ALS, the study reagent has been
used in a group of patients with predeﬁned clinical features
[27]. It might be the ﬁrst step toward tailoring treatments for
prospectively stratiﬁed patients with the scope to identify
patients' groups who will most likely proﬁt from given
therapeutic agents.
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